FIELD: pharmaceuticals.
SUBSTANCE: invention refers to a compound of formula I:
(I)
or its pharmaceutically acceptable salt, where: L1 is -CH2-; R20 is , unsubstituted pyridyl, unsubstituted furanyl or unsubstituted thiophenyl; or L1-R20 is ; R1 and R4 are hydrogen; R2 denotes hydrogen or halogen; R3 is -NO2, -CN or halogen; R5 denotes hydrogen, -NO2 or -NH2; or R2 and R3 are bonded to form, together with atoms, to which they are attached, , R6 is hydrogen or halogen; R7 is hydrogen; R8 denotes hydrogen or halogen; R9 denotes hydrogen, -CH3 or halogen; R10 and R11 are hydrogen or halogen and R12, R13 and R14 are hydrogen, which activate CFTR.
EFFECT: as a result, CFTR regulators and methods of their application are proposed.
41 cl, 25 dwg, 6 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
CFTR REGULATORS AND METHODS FOR USE THEREOF | 2016 |
|
RU2742934C2 |
CFTR REGULATORS AND THEIR APPLICATION METHODS | 2016 |
|
RU2749834C2 |
OPHTHALMIC PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2818087C2 |
CHEMOKINE RECEPTOR MODULATORS AND USE THEREOF | 2017 |
|
RU2768827C2 |
AMYLOID-BINDING AGENTS | 2010 |
|
RU2517174C2 |
METALLOPORPHYRIN TREATMENT OF NEUROLOGICAL DISEASES | 2012 |
|
RU2623207C2 |
DERIVATIVES OF AMINOINDAZOLS AND THEIR APPLICATION AS KINASES INHIBITORS | 2003 |
|
RU2339624C2 |
KINASE MODULATORS BASED ON PYRROLOPYRIDINE DERIVATIVES | 2005 |
|
RU2389728C2 |
KINASES MODULATION AND INDICATIONS FOR ITS USE | 2012 |
|
RU2631487C2 |
METHOD OF TREATING DISORDERS ASSOCIATED WITH ALKYLATING AGENT EXPOSURE | 2009 |
|
RU2506083C2 |
Authors
Dates
2020-08-26—Published
2016-12-23—Filed